最新ニュース Enovix (NASDAQ:ENVX) 株価情報

ENOVIX CORP

Enovix

Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, Norway, the United States, Taiwan, and other regions.

Mid Cap

News

Movers

CRDO

DJTWW

ENVX

FIZZ

GLBE

GRND

KVYO

STAA

TGLS

先週、これらの中型株は最も優れた業績を発揮しました。あなたのポートフォリオには含まれていますか？

中小株式市場　今週注目の10銘柄

Enovix Corp

Craig-Hallum analyst Anthony Stoss maintains Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) with a Buy and lowers the price target from $8 to $6.

Price Target

Analyst Ratings

INDI

Craig-Hallum Maintains Buy on Indie Semiconductor, Lowers Price Target to $6

General

CIFR

Engie North America Partners With Cipher Mining To Enter Into A Power Supply Agreement To Power A Cipher Data Center In Texas; Once Executed, The Agreement Would Allow Cipher To Purchase Up To 300MW Of Clean Energy From One Of Engie's Wind Facilities

ACELYRIN, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRN#NASDAQ">SLRN</a>), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company's special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company's merger agreement with Alumis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>). As previously announced, under the terms of the amended merger agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction.
ACELYRIN expects to complete the transaction in the second quarter of 2025.

ALMS

SLRN

ACELYRIN Stockholders Approve Merger With Alumis, Securing 0.4814 Shares Per ACELYRIN Share At Closing

Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-14. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Strata Skin Sciences will report an earnings per share (EPS) of $-0.44.
Investors in Strata Skin Sciences are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
The company's EPS beat by $0.23 in the last quarter, leading to a 0.74% drop in the share price on the following day.

<img src="https://www.benzinga.com/files/images/story/2025/1747156042_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Strata Skin Sciences were trading at $2.55 as of May 09. Over the last 52-week period, shares are down 39.29%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analysts' Take on Strata Skin Sciences</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Strata Skin Sciences.
With 1 analyst ratings, Strata Skin Sciences has a consensus rating of Buy. The average one-year price target is $6.0, indicating a potential 135.29% upside.
<h3>Analyzing Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Co-Diagnostics and Ekso Bionics Holdings, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Co-Diagnostics, with an average 1-year price target of $5.5, suggesting a potential 115.69% upside.</li>
<li>Analysts currently favor an Buy trajectory for Ekso Bionics Holdings, with an average 1-year price target of $4.67, suggesting a potential 83.14% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Co-Diagnostics and Ekso Bionics Holdings, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strata Skin Sciences</td>
<td>Buy</td>
<td>10.21%</td>
<td>$5.76M</td>
<td>-62.83%</td>
</tr>
<tr>
<td>Co-Diagnostics</td>
<td>Buy</td>
<td>-95.80%</td>
<td>$-105.74K</td>
<td>-18.68%</td>
</tr>
<tr>
<td>Ekso Bionics Holdings</td>
<td>Buy</td>
<td>-10.14%</td>
<td>$1.81M</td>
<td>-24.54%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Strata Skin Sciences ranks highest in Revenue Growth among its peers. It has the highest Gross Profit margin. However, it has the lowest Return on Equity.
<h3>Delving into Strata Skin Sciences's Background</h3>
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
<h3>Financial Insights: Strata Skin Sciences</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Strata Skin Sciences showcased positive performance, achieving a revenue growth rate of 10.21% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Strata Skin Sciences's net margin is impressive, surpassing industry averages. With a net margin of -46.96%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Strata Skin Sciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -62.83%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Strata Skin Sciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -11.78%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 3.31, caution is advised due to increased financial risk.
<a href="https://www.benzinga.com/quote/SSKN/earnings">To track all earnings releases for Strata Skin Sciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

SSKN

A Peek at Strata Skin Sciences's Future Earnings

PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) will release its quarterly earnings report on Wednesday, 2025-05-14. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate PDS Biotechnology to report an earnings per share (EPS) of $-0.22.
The market awaits PDS Biotechnology's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.07, leading to a 0.8% increase in the share price on the subsequent day.
Here's a look at PDS Biotechnology's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.28</td>
<td>-0.28</td>
<td>-0.34</td>
<td>-0.37</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.21</td>
<td>-0.29</td>
<td>-0.23</td>
<td>-0.30</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-11.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747156017_0.png" alt="eps graph" />
<h3>PDS Biotechnology Share Price Analysis</h3>
Shares of PDS Biotechnology were trading at $1.29 as of May 12. Over the last 52-week period, shares are down 64.03%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/PDSB/earnings">To track all earnings releases for PDS Biotechnology visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PDSB

Insights Ahead: PDS Biotechnology's Quarterly Earnings

<h3>Gainers</h3>
<ul>
<li>Lobo EV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) stock rose 105.9% to $1.56 during Tuesday's regular session. The company's market cap stands at $13.5 million. </li>
<li>Landsea Homes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) stock rose 60.15% to $11.23. The market value of their outstanding shares is at $409.0 million. The company's, Q1 earnings came out yesterday. </li>
<li>Century Casinos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTY#NASDAQ">CNTY</a>) stock rose 21.76% to $1.79. The market value of their outstanding shares is at $54.9 million. The company's, Q1 earnings came out yesterday. </li>
<li>Big 5 Sporting Goods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGFV#NASDAQ">BGFV</a>) stock increased by 18.31% to $1.2. The market value of their outstanding shares is at $27.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Netclass Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCL#NASDAQ">NTCL</a>) shares decreased by 26.5% to $21.32 during Tuesday's regular session. The market value of their outstanding shares is at $380.1 million. </li>
<li>China Liberal Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) shares decreased by 22.17% to $1.58. The company's market cap stands at $425.5 million. </li>
<li>Superior Industries Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) shares fell 20.52% to $0.64. The company's market cap stands at $18.3 million. The company's, Q1 earnings came out yesterday. </li>
<li>Tilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLYS#NYSE">TLYS</a>) shares decreased by 18.48% to $0.95. The company's market cap stands at $28.5 million. </li>
<li>WW International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) shares fell 17.82% to $0.31. The company's market cap stands at $25.0 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGP#NASDAQ">QVCGP</a>) shares declined by 13.79% to $13.38. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGFV

CLEU

CNTY

LOBO

LSEA

NTCL

QVCGP

TLYS

10 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) stock increased by 173.1% to $14.23 during Tuesday's regular session. The market value of their outstanding shares is at $15.9 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares increased by 40.75% to $1.03. The market value of their outstanding shares is at $53.2 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 38.01% to $1.67. The market value of their outstanding shares is at $4.9 million. </li>
<li>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) stock moved upwards by 33.33% to $1.76. The market value of their outstanding shares is at $273.0 million. The company's, Q1 earnings came out today. </li>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) stock moved upwards by 27.6% to $1.41. The market value of their outstanding shares is at $53.2 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) stock moved upwards by 27.57% to $1.94. The company's market cap stands at $46.1 million. The company's, Q4 earnings came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock decreased by 91.4% to $0.03 during Tuesday's regular session. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares declined by 64.03% to $4.83. The market value of their outstanding shares is at $228.9 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock fell 38.48% to $0.08. The company's market cap stands at $2.0 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock decreased by 38.31% to $290.0. The company's market cap stands at $3.7 billion. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) stock fell 36.51% to $0.47. The market value of their outstanding shares is at $106.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock decreased by 25.95% to $49.31. The market value of their outstanding shares is at $6.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APYX

AXDX

CELU

CNSP

HALO

HCWB

HUMA

PLRZ

SGMO

ZYBT

12 Health Care Stocks Moving In Tuesday's Intraday Session

eGain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGAN#NASDAQ">EGAN</a>) is preparing to release its quarterly earnings on Wednesday, 2025-05-14. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect eGain to report an earnings per share (EPS) of $0.07.
Anticipation surrounds eGain's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company beat EPS by $0.02, leading to a 18.18% drop in the share price the following trading session.
Here's a look at eGain's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.02</td>
<td>0</td>
<td>0.02</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.04</td>
<td>0.04</td>
<td>0.08</td>
<td>0.08</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-18.0%</td>
<td>-7.000000000000001%</td>
<td>-14.000000000000002%</td>
<td>-13.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747156001_0.png" alt="eps graph" />
<h3>Performance of eGain Shares</h3>
Shares of eGain were trading at $5.1 as of May 12. Over the last 52-week period, shares are down 12.65%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/EGAN/earnings">To track all earnings releases for eGain visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EGAN

Earnings Preview: eGain

<h3>Gainers</h3>
<ul>
<li>Lichen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) stock rose 112.1% to $7.38 during Tuesday's regular session. The company's market cap stands at $4.4 million. </li>
<li>Babcock &amp; Wilcox Enterprises, Inc. 6.50% Senior Notes due 2026 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWNB#NYSE">BWNB</a>) shares moved upwards by 39.63% to $10.78. </li>
<li>Northann (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NCL#AMEX">NCL</a>) stock rose 37.9% to $0.59. The company's market cap stands at $32.5 million. </li>
<li>Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) stock moved upwards by 31.99% to $3.15. The market value of their outstanding shares is at $1.0 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>VirTra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) stock moved upwards by 31.26% to $6.13. The market value of their outstanding shares is at $69.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>TrueBlue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBI#NYSE">TBI</a>) shares increased by 27.84% to $5.95. The company's market cap stands at $176.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) stock declined by 25.2% to $1.91 during Tuesday's regular session. The company's market cap stands at $258.4 million. The company's, Q1 earnings came out yesterday. </li>
<li>Rain Enhancement (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIN#NASDAQ">RAIN</a>) shares declined by 23.05% to $6.02. The market value of their outstanding shares is at $45.6 million. </li>
<li>High-Trend International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) shares declined by 16.48% to $1.45. The market value of their outstanding shares is at $175.3 million. </li>
<li>Hertz Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) shares declined by 15.57% to $5.86. The company's market cap stands at $1.7 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Nuburu (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BURU#AMEX">BURU</a>) stock declined by 14.16% to $0.14. The company's market cap stands at $6.9 million. </li>
<li>Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) shares declined by 11.85% to $0.76. The market value of their outstanding shares is at $78.2 million. As per the press release, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLNK

BURU

BWNB

HTCO

LICN

MVST

Nuveen Insured California Premium Fund Ii

RAIN

VTSI

12 Industrials Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Life360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIF#NASDAQ">LIF</a>) shares rose 24.5% to $61.63 during Tuesday's regular session. The company's market cap stands at $4.7 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) stock moved upwards by 21.93% to $190.47. The market value of their outstanding shares is at $20.4 billion. </li>
<li>Thumzup Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>) shares increased by 20.27% to $7.86. The market value of their outstanding shares is at $74.0 million. </li>
<li>Electro-Sensors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELSE#NASDAQ">ELSE</a>) shares increased by 19.39% to $5.01. The company's market cap stands at $17.2 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Maxeon Solar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>) stock moved upwards by 18.87% to $4.22. The market value of their outstanding shares is at $70.5 million. </li>
<li>Vuzix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VUZI#NASDAQ">VUZI</a>) stock moved upwards by 18.8% to $2.5. The company's market cap stands at $190.2 million. The company's, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Exodus Movement (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EXOD#AMEX">EXOD</a>) shares decreased by 25.8% to $40.27 during Tuesday's regular session. The market value of their outstanding shares is at $1.1 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) stock declined by 22.35% to $2.43. The market value of their outstanding shares is at $24.2 million. </li>
<li>Sonim Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) shares decreased by 19.47% to $1.2. The company's market cap stands at $5.8 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) shares declined by 17.11% to $4.75. The company's market cap stands at $169.7 million. As per the press release, Q1 earnings came out today. </li>
<li>Abits Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) stock decreased by 16.63% to $3.16. The market value of their outstanding shares is at $7.4 million. </li>
<li>Baijiayun Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>) shares fell 14.68% to $0.29. The company's market cap stands at $8.6 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABTS

ELSE

EXOD

FSLR

MASS

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MLGO

SONM

TZUP

VUZI

12 Information Technology Stocks Moving In Tuesday's Intraday Session

WIIM

Boeing shares are trading higher after AviLease placed an order for Boeing 737 MAX jets.

Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) is preparing to release its quarterly earnings on Wednesday, 2025-05-14. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Aterian to report an earnings per share (EPS) of $-0.70.
Aterian bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company beat EPS by $0.45, leading to a 27.96% increase in the share price the following trading session.

<img src="https://www.benzinga.com/files/images/story/2025/1747155918_0.png" alt="eps graph" />
<h3>Aterian Share Price Analysis</h3>
Shares of Aterian were trading at $2.18 as of May 12. Over the last 52-week period, shares are down 31.09%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/ATER/earnings">To track all earnings releases for Aterian visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATER

Exploring Aterian's Earnings Expectations

Luminar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-14. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Luminar Technologies will report an earnings per share (EPS) of $-1.63.
Investors in Luminar Technologies are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
Last quarter the company beat EPS by $0.75, which was followed by a 32.96% increase in the share price the next day.
Here's a look at Luminar Technologies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-2.17</td>
<td>-2.55</td>
<td>-2.85</td>
<td>-3</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.42</td>
<td>-2.40</td>
<td>-2.70</td>
<td>-2.85</td>
</tr>
<tr>
<td>Price Change %</td>
<td>33.0%</td>
<td>11.0%</td>
<td>-37.0%</td>
<td>19.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747155899_0.png" alt="eps graph" />
<h3>Tracking Luminar Technologies's Stock Performance</h3>
Shares of Luminar Technologies were trading at $4.6 as of May 12. Over the last 52-week period, shares are down 82.94%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/LAZR/earnings">To track all earnings releases for Luminar Technologies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LAZR

What to Expect from Luminar Technologies's Earnings

Benchmark analyst Nathan Martin maintains Ramaco Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METC#NASDAQ">METC</a>) with a Buy and lowers the price target from $18 to $14.

METC

Benchmark Maintains Buy on Ramaco Resources, Lowers Price Target to $14

Creative Realities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREX#NASDAQ">CREX</a>) will release its quarterly earnings report on Wednesday, 2025-05-14. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Creative Realities to report an earnings per share (EPS) of $-0.12.
The announcement from Creative Realities is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.16, leading to a 0.0% drop in the share price on the subsequent day.
Here's a look at Creative Realities's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.11</td>
<td>-0.02</td>
<td>-0.07</td>
<td>-0.09</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.27</td>
<td>0.01</td>
<td>-0.06</td>
<td>-0.01</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-11.0%</td>
<td>3.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747155878_0.png" alt="eps graph" />
<h3>Market Performance of Creative Realities's Stock</h3>
Shares of Creative Realities were trading at $1.66 as of May 12. Over the last 52-week period, shares are down 52.16%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/CREX/earnings">To track all earnings releases for Creative Realities visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CREX

Examining the Future: Creative Realities's Earnings Outlook

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.taskus.com%2Fen-us%2F&amp;esheet=54254082&amp;newsitemid=20250513328260&amp;lan=en-US&amp;anchor=TaskUs%2C+Inc.&amp;index=1&amp;md5=7c4207ec4c264caca3f5c34bad83f3c0">TaskUs, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TASK#NASDAQ">TASK</a>), a leading provider of outsourced digital services and next-generation customer experience to the world's most innovative companies, today announced strategic partnerships with Decagon and Regal. Together with these two elite agentic AI platform companies, TaskUs will aim to further transform customer support through intelligent automation.
The partnerships with Decagon and Regal augments TaskUs' <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.taskus.com%2Fpress-release%2Ftaskus-launches-agentic-ai-consulting-practice-to-lead-businesses-through-the-ai-era%2F&amp;esheet=54254082&amp;newsitemid=20250513328260&amp;lan=en-US&amp;anchor=recently+announced&amp;index=2&amp;md5=d3a960e473b68c19e755330023b39f69">recently announced</a> agentic AI consulting practice, a set of business services and expertise that help companies seamlessly integrate advanced AI technologies into their customer experience operations.

TASK

TaskUs Announces Strategic Partnerships With Decagon And Regal To Further Transform Customer Support Through Intelligent Automation

Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-14. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Grove Collaborative Hldgs will report an earnings per share (EPS) of $-0.04.
Anticipation surrounds Grove Collaborative Hldgs's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
The company's EPS missed by $0.06 in the last quarter, leading to a 2.41% drop in the share price on the following day.
Here's a look at Grove Collaborative Hldgs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.15</td>
<td>-0.13</td>
<td>-0.14</td>
<td>-0.16</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.21</td>
<td>-0.04</td>
<td>-0.28</td>
<td>-0.10</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-12.0%</td>
<td>-6.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747155822_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Grove Collaborative Hldgs were trading at $1.22 as of May 12. Over the last 52-week period, shares are down 22.23%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/GROV/earnings">To track all earnings releases for Grove Collaborative Hldgs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GROV

Grove Collaborative Hldgs's Earnings Outlook

Trading Ideas

GOOG

GOOGL

LDOS

UBER

CNBC Halftime Report Final Trades: Alphabet, Banco Santander, Leidos Holdings, Uber Technologies

lumis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRN#NASDAQ">SLRN</a>) at its Special Meeting of Stockholders.
The final voting results of the Alumis Special Meeting will be reported in a Form 8-K filed by Alumis with the U.S. Securities and Exchange Commission.
The merger is expected to close in the second quarter of 2025, subject to satisfaction of certain customary closing conditions.

Lumis Stockholders Approve All Proposals Required To Be Approved In Connection With Pending Merger With ACELYRIN; Merger Is Expected To Close In Q2 2025

LeddarTech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) is preparing to release its quarterly earnings on Wednesday, 2025-05-14. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect LeddarTech Holdings to report an earnings per share (EPS) of $-0.34.
The announcement from LeddarTech Holdings is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS missed by $0.51, leading to a 2.85% increase in the share price on the subsequent day.
Here's a look at LeddarTech Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.35</td>
<td></td>
<td>-0.26</td>
<td>-0.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.86</td>
<td>-2.72</td>
<td>-0.23</td>
<td>-0.45</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-4.0%</td>
<td>2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<h3>LeddarTech Holdings Share Price Analysis</h3>
Shares of LeddarTech Holdings were trading at $0.6348 as of May 12. Over the last 52-week period, shares are down 68.26%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/LDTC/earnings">To track all earnings releases for LeddarTech Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LDTC

Earnings Preview: LeddarTech Holdings

Press Releases

Enovix Completes Site Acceptance Testing (SAT) of Fab2

Enovix Secures Landmark Purchase Order for Silicon Batteries

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enovix Corporation- ENVX

Enovix to Release Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Glancy Prongay & Murray LLP Announces Investigation of Enovix Corporation (ENVX)

Enovix Announces Fourth Quarter and Full Year 2024 Financial Results

Enovix Reports Progress on 2025 Smartphone Launch

Enovix To Acquire Korean Battery Cell Facility to Bolster Manufacturing

Management

Enovix Appoints Ryan Benton as Chief Financial Officer

Enovix Announces First Quarter 2025 Financial Results

ADS-TEC Energy

AMETEK

American Superconductor Corporation - Common Stock

American Superconductor

Array Technologies

Atkore

Acuity

Emerson Electric

EnerSys

Eos Energy Enterprises, Inc. - Common Stock

Eos Energy Enterprises

Eaton Corp

Fluence Energy, Inc. - Class A Common Stock

Fluence Energy

Generac Hldgs

Hubbell

nVent Electric

NEXTracker

Preformed Line Products Company - Common Stock

Preformed Line Products

Plug Power

Powell Industries

Rockwell Automation

Regal Rexnord

Sunrun

Shoals Technologies Group, Inc. - Class A Common Stock

Shoals Technologies Gr

Thermon Group Holdings, Inc. Common Stock

Thermon Group Holdings

Vicor

Vertiv Holdings, LLC Class A Common Stock

Vertiv Holdings

JP Morgan

TD Securities

B. Riley Securities

Benchmark

Craig-Hallum

先週、これらの中型株は最も優れた業績を発揮しました。あなたのポートフォリオには含まれていますか？
<ol>
<li>米国株式市場（NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>）の株価は、同社のTempus ECG-AFデバイスが米国食品医薬品局（FDA）の510（k）の認可を取得したと発表したことを受けて30.43％上昇しました。このデバイスは、心房細動/フラッターのリスクが高いと考えられる患者を特定するのにAIが用いられています。</li>
<li>米国株式市場（NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>）の株価は、アジアの大手家電バッテリーパックメーカーであるElentecがEnovix Corporationと覚書（MOU）に調印したことを発表した後、29.70％上昇しました。</li>
<li>Grindr Inc. （NYSE：<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>）の株式は、同社が<a href="https://www.benzinga.com//node/39504431" target="_blank" rel="noreferrer noopener">初の投資家向け説明会</a>を先取りして、今年の収益見通しを引き上げたことを受けて27.50％急伸しました。</li>
<li>Trump Media &amp; Technology Group Corp. （NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/DJTWW#NASDAQ">DJTWW</a>）の株式ワラントは、同社が2024年6月20日と21日に<a href="https://www.benzinga.com//node/39453772" target="_blank" rel="noreferrer noopener">現金による権利行使によって6940万ドル以上を受領することを期待している</a>と発表した後、18.33％上昇しました。</li>
<li>Credo Technology Group（NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>）の株価は、TD Cowenが同社の株をBuyに格上げし、<a href="https://www.benzinga.com/quote/CRDO/analyst-ratings" target="_blank" rel="noreferrer noopener">株価目標を24ドルから35ドルに引き上げたことを受けて18.30％急騰しました</a>。</li>
<li>Tecnoglass Inc.（NYSE：<a class="ticker" href="https://www.benzinga.com/stock/TGLS#NYSE">TGLS</a>）の株価は、同社が取締役会で戦略的な選択肢を検討していることを発表した後、17.90％上昇しました。また、同社は<a href="https://www.benzinga.com//node/39489521" target="_blank" rel="noreferrer noopener">2024年のFY24業績見通しを再確認しました</a>。</li>
<li>STAAR Surgical Company（NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>）の株価は、16.55％上昇しています。</li>
<li>RXO Inc.（NYSE：<a class="ticker" href="https://www.benzinga.com/stock/EXO#NYSE">EXO</a>）の株価は、先週、UPSから<a href="https://www.benzinga.com//node/39453065" target="_blank" rel="noreferrer noopener">Coyote Logisticsが買収されると発表されたことを受けて16.22%上昇しました。</a></li>
<li>Global-E Online Ltd（NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>）の株価は先週、16.21%上昇しました。</li>
<li>SentinelOne Inc（NYSE：<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>）の株価は、DA Davidsonが同社の株に対するNeutral投資評価を維持し、株価予測を17ドルから18.5ドルに引き上げたことを受けて15.47%上昇しました。</li>
</ol>

Comments

Enovix

ニュース

最新ニュース Enovix (NASDAQ:ENVX) 株価情報

月曜日, 7 01, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル